Dolutegravir 50mg Tablet

Dolutegravir 50mg Tablet contains dolutegravir, an HIV-1 integrase strand transfer inhibitor used in combination with other antiretroviral medicines. Generic dolutegravir 50mg is an alternative to Tivicay® 50mg, with manufacturer, excipients and packaging varying by product. Local terminology includes Dolutegravir 50 mg Tabletten, dolutégravir 50 mg, 돌루테그라비르 50mg and долутегравир 50 мг.

Product Information

Generic Name

Dolutegravir

Strength

50mg

Active Ingredient

Dolutegravir, as dolutegravir sodium

Dosage Form

Film-Coated Tablet

Route

Oral

Drug Class

HIV-1 Integrase Strand Transfer Inhibitor (INSTI)

Reference Brand

Tivicay® 50mg

Therapeutic Area

HIV / Antiretroviral Therapy

Prescription Status

Prescription medicine

Manufacturer

Varies by generic product

Pack Size

Varies by country and manufacturer

Dolutegravir 50mg for HIV Treatment

Dolutegravir is used with other antiretroviral medicines for treatment of HIV-1 infection. Current U.S. labeling covers adults and pediatric patients in specified age/weight groups, while UK and EU product information also positions Tivicay as combination antiretroviral therapy.

Generic Tivicay® 50mg

Tivicay® is the reference dolutegravir product. Generic dolutegravir 50mg contains the same active ingredient but may differ in manufacturer, inactive ingredients, tablet markings and packaging.

EMA has specific bioequivalence guidance for dolutegravir 50mg film-coated tablets, supporting the development of generic products in this dosage form.

Commercial Availability

High-intent searches include dolutegravir 50mg price, dolutegravir 50mg tablet price, generic dolutegravir 50mg, generic Tivicay 50mg, Tivicay 50mg, dolutegravir 50mg pharmacy, dolutegravir 50mg cost and dolutegravir 50mg buy.

Russia currently has both Tivicay 50mg and multiple registered generic dolutegravir 50mg film-coated tablet products, including 30-tablet presentations.

Dolutegravir requires prescription supervision because clinically important interactions and adverse reactions can occur. Current labeling highlights hypersensitivity reactions, hepatotoxicity and drug interactions. Dolutegravir also has important interaction considerations with certain enzyme inducers and products containing polyvalent cations such as calcium or iron.